ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ERYP Erytech Pharma SA

0.78
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
Erytech Pharma SA NASDAQ:ERYP NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 0.78 0.77 0.9091 0 01:00:00

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

21/06/2023 11:10am

Edgar (US Regulatory)



UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 6-K
________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2023
Commission File Number: 001-38281
________________________
ERYTECH Pharma S.A.
(Translation of registrant’s name into English)
________________________

60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 Form 20-F S             Form 40-F £  



















INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Press release

On June 20, 2023, ERYTECH Pharma S.A. issued a press release to announce the filing of a new lawsuit by Akkadian Partners.

The full text of the press release is attached as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.



EXHIBIT INDEX
ExhibitDescription
99.1Press Release dated June 20, 2023.























SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ERYTECH Pharma S.A.
Date:
June 21, 2023
By:
/s/ Eric Soyer
Name Eric Soyer
Title: Chief Financial Officer and Chief Operating Officer

1 Year Erytech Pharma Chart

1 Year Erytech Pharma Chart

1 Month Erytech Pharma Chart

1 Month Erytech Pharma Chart

Your Recent History

Delayed Upgrade Clock